Andy Blidy

🦉 Cancer Immunotherapy: A Week of Clinical Breakthroughs and Unexpected Discoveries October 25–31, 2026 | Weekly Research Digest A Phase III trial has challenged the standard first-line treatment for PD-L1-negative lung cancer. Meanwhile, new studies show that dendritic cells, mitochondrial DNA, tumor metabolism, and even blood platelets can determine whether cancer immunity succeeds or fails. 🩸 1. Lung Cancer: A 51% Reduction in Progression Risk In the randomized Phase III OptiTROP-Lung06 trial (n=455), sacituzumab tirumotecan plus pembrolizumab extended median progression-free survival to 15.0 months versus 5.7 months with chemotherapy plus pembrolizumab in PD-L1-negative advanced nonsquamous NSCLC (HR 0.49; p<0.001). Response rates were similar (50.2% vs. 47.3%), but response duration doubled. Grade ≥3 adverse events occurred in 47.6% versus 60.6%. Overall survival remains immature. Access: NEJM abstract publicly available; unrestricted full-text access not confirmed. nejm.org/doi/10.1056/NEJMoa2… 🩸 2. Personalized Cancer Vaccines Pass the Phase III Test At ESMO 2026, Merck and Moderna reported that adding personalized mRNA neoantigen therapy intismeran autogene to pembrolizumab improved 24-month recurrence-free survival in resected melanoma from 70.0% to 82.2% (n=1,137; HR 0.58). Distant-metastasis-free survival also improved (HR 0.62). This is the first positive Phase III trial of individualized neoantigen therapy against an active immunotherapy standard. Overall survival remains immature, while personalized manufacturing presents a substantial logistical challenge. ESMO data presented October 24; included as an exceptional lookback. esmo.org/insights-by-esmo/al… 🩸 3. The Real Target of a Bispecific Antibody May Not Be the Tumor An Immunity study found that PD-L1×4-1BB bispecific antibody activity depended on PD-L1-positive cDC1 dendritic cells rather than PD-L1 expression on malignant cells. Antitumor efficacy required antigen cross-presentation, IL-12, and CD40L-mediated dendritic-cell licensing. Increasing dendritic-cell abundance with Flt3L further strengthened tumor control. The finding challenges tumor PD-L1 expression as a sufficient guide to this therapeutic mechanism. Evidence remains predominantly preclinical. Access: Subscription/paywall; abstract publicly available. doi.org/10.1016/j.immuni.202… 🩸 4. Mitochondrial DNA Determines Whether Cancer Cell Death Activates Immunity An Immunity study identified mitochondrial DNA release as a determinant of whether stressed cancer cells undergo immunogenic death or conventional apoptosis. MEK inhibition triggered mitochondrial DNA release in KRAS-mutant cancer cells, but PRKN-mediated mitophagy suppressed the resulting cGAS–STING response. Blocking mitophagy restored immune activation and strengthened CD8+ T-cell-mediated tumor control in preclinical models. The result suggests that mitochondrial quality control may decide whether targeted cancer therapy generates an immune response. Access: Publisher full text not verified; indexed abstract publicly available. doi.org/10.1016/j.immuni.202… 🩸 5. Blood Platelets Can Suppress Brain Tumor Immunity A Cancer Cell study identified platelet PAR4 signaling as an unexpected regulator of antitumor immunity in glioblastoma. Platelet activation suppressed cytotoxic T-cell activity. In preclinical models, blocking PAR4 relieved immune suppression and improved survival in females but not males, suggesting sex-dependent interactions between coagulation, hormones, and tumor immunity. The findings reveal a possible therapeutic target outside conventional immune checkpoints. Human efficacy remains unproven. Access: Publisher full-text access not verified; research summary publicly available. doi.org/10.1016/j.ccell.2026… 🩸 6. A Metabolic Enzyme Shields Tumors from Killer T Cells A Nature Cancer study identified GALE, a sugar-metabolism enzyme, as a tumor-intrinsic checkpoint restricting Vγ9Vδ2 T-cell killing. GALE modifies cell-surface glycosylation, strengthening inhibitory CD155–TIGIT and CEACAM1–TIM3 interactions. GALE loss enhanced tumor killing in mouse models and patient-derived organoids. The finding suggests that modifying tumor metabolism could strengthen HLA-independent immunotherapy. Clinical feasibility and safety remain unknown. nature.com/articles/s43018-0… 🩸 7. Lung Cancer TIL Therapy Finds Its Responders Iovance reported a 24.6% objective response rate with lifileucel in 69 previously treated NSCLC patients. Responses reached 59.1% (13/22) in a retrospectively selected KRAS-wild-type/HER2-wild-type subgroup with a smoking history. The finding could shift tumor-infiltrating lymphocyte therapy toward molecular patient selection. Iovance plans prospective validation through POSITILITY. The subgroup is small, retrospectively defined, and vulnerable to selection bias. rss.globenewswire.com/news-r… 🩸 8. Dual Checkpoint–VEGF Therapy Shows Activity After Resistance BioNTech and Bristol Myers Squibb reported a 36.7% confirmed response rate with pumitamig, a PD-L1×VEGF-A bispecific, plus docetaxel after progression on chemo-immunotherapy in metastatic NSCLC. Median progression-free survival was 6.9 months. The signal suggests possible activity after checkpoint inhibitor failure, but the Phase II study was single-arm, with only 30 efficacy-evaluable patients and 12.2 weeks of median follow-up. Superiority remains unproven. biontech.com/int/en/home/med… 🩸 9. A New CAR-T Target Emerges in Childhood Cancer Nature Communications researchers used cell-surface proteomics of patient-derived malignant rhabdoid tumor organoids to identify ROBO1 as a potential CAR-T target. ROBO1-directed CAR-T cells eliminated tumor cells in organoid models and improved survival in tumor-bearing mice. The approach may extend to other pediatric solid tumors, but normal-tissue expression and on-target/off-tumor toxicity remain critical clinical barriers. nature.com/articles/s41467-0… 🩸 10. AI Cuts Immunotherapy Safety Review Time by 43.5% A Nature Cancer study found that agentic AI combined with human review reduced median annotation time for immune-related adverse events by 43.5%, while improving reviewer consistency. Retrospective detection performance was strong, but accuracy weakened in prospective clinical deployment. The technology could improve toxicity surveillance, although faster detection has not yet been shown to reduce severe adverse events or hospitalizations. nature.com/articles/s43018-0… 🩸 11. Immunotherapy Blurs the Boundary Between Surgery and Radiation In the Phase II MDT-BRIDGE trial, neoadjuvant durvalumab plus chemotherapy enabled surgical resection in 74.6% of 142 patients with resectable or borderline-resectable NSCLC. Another 25 patients proceeded to chemoradiotherapy. The strategy adapts definitive treatment to post-immunotherapy resectability rather than committing patients to a fixed pathway. It demonstrates feasibility, not an overall-survival advantage; the study lacked a randomized comparator. nature.com/articles/s41591-0… 🩸 12. CAR-T Reveals an Unexpected Immune Complication A Blood study investigated EBV-positive lymphoproliferative disease following CD7 CAR-T therapy. Multi-omics analysis implicated dysfunctional CD7-negative T cells and IDO1-positive macrophage niches in an environment favoring EBV-driven B-cell transformation. The findings raise a safety concern beyond conventional CAR-T toxicities such as CRS and ICANS. However, the complication is uncommon, and the study does not establish its incidence or prove that CD7 CAR-T directly causes it. ashpublications.org/blood/ar… 🩸 Regulatory & Clinical Watch No major new FDA cancer immunotherapy approval was identified during October 25–31. The strongest clinical evidence came from randomized Phase III trials combining immune checkpoint blockade with personalized vaccines or antibody-drug conjugates. Emerging mechanistic studies challenge the assumption that tumor-cell biomarkers alone adequately predict immunotherapy activity. The week's underlying signal: The next advances in cancer immunotherapy may come from controlling where and how immune responses begin—not simply increasing their intensity. Antigen presentation, mitochondrial stress, dendritic-cell interactions, platelet signaling, and molecular patient selection are becoming consequential therapeutic variables.